JPI-547 not checked

Onconic Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
6 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“The dose levels will be escalated following a 3+3 dose escalation scheme.”In the company’s words, NCT07364422 on ClinicalTrials.gov
Tested for
Ovarian Cancer, Gastric Cancer (GC), Pancreatic Ductal Adenocarcinoma
Main trialPhase 2
“This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients”In the company’s words, NCT07370818 on ClinicalTrials.gov

Other drugs for Ovarian Cancer

All 265 drugs for Ovarian Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting 31 Dec 2029 To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
Phase 1/2Not yet recruiting 28 Feb 2026 To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Phase 1/2Recruiting Apr 2030 Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
Phase 1Not yet recruiting Jul 2026 Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants
Phase 2Unknown Nov 2024 A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
Phase 1Completed 14 Dec 2021 A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow JPI-547

Following is part of Solo: you see every change to JPI-547 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in